Apellis Pharmaceuticals I... (APLS)
Apellis Pharmaceuticals Statistics
Share Statistics
Apellis Pharmaceuticals has 125.68M shares outstanding. The number of shares has increased by 3.42% in one year.
| Shares Outstanding | 125.68M |
| Shares Change (YoY) | 3.42% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 104.6M |
| Failed to Deliver (FTD) Shares | 3.29K |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 26.83M, so 21.35% of the outstanding shares have been sold short.
| Short Interest | 26.83M |
| Short % of Shares Out | 21.35% |
| Short % of Float | 28.16% |
| Short Ratio (days to cover) | 8.71 |
Valuation Ratios
The PE ratio is -19.98 and the forward PE ratio is 112.88. Apellis Pharmaceuticals's PEG ratio is 0.31.
| PE Ratio | -19.98 |
| Forward PE | 112.88 |
| PS Ratio | 5.57 |
| Forward PS | 1.5 |
| PB Ratio | 17.3 |
| P/FCF Ratio | -44.79 |
| PEG Ratio | 0.31 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Apellis Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 2.06.
| Current Ratio | 4.25 |
| Quick Ratio | 3.81 |
| Debt / Equity | 2.06 |
| Debt / EBITDA | -1.99 |
| Debt / FCF | -5.32 |
| Interest Coverage | -5.85 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $-280.68K |
| Employee Count | 705 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | 1.16M |
| Effective Tax Rate | -0.59% |
Stock Price Statistics
The stock price has increased by -57.7% in the last 52 weeks. The beta is 0.84, so Apellis Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -57.7% |
| 50-Day Moving Average | 22.51 |
| 200-Day Moving Average | 30.01 |
| Relative Strength Index (RSI) | 50.35 |
| Average Volume (20 Days) | 2.07M |
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 709.95M and earned -197.88M in profits. Earnings per share was -1.6.
| Revenue | 709.95M |
| Gross Profit | 592.23M |
| Operating Income | -236.39M |
| Net Income | -197.88M |
| EBITDA | -236.39M |
| EBIT | -237.11M |
| Earnings Per Share (EPS) | -1.6 |
Balance Sheet
The company has 411.29M in cash and 469.78M in debt, giving a net cash position of -58.49M.
| Cash & Cash Equivalents | 411.29M |
| Total Debt | 469.78M |
| Net Cash | -58.49M |
| Retained Earnings | -3.04B |
| Total Assets | 885.05M |
| Working Capital | 603.45M |
Cash Flow
In the last 12 months, operating cash flow was -87.87M and capital expenditures -403K, giving a free cash flow of -88.27M.
| Operating Cash Flow | -87.87M |
| Capital Expenditures | -403K |
| Free Cash Flow | -88.27M |
| FCF Per Share | -0.71 |
Margins
Gross margin is 83.42%, with operating and profit margins of -33.3% and -27.87%.
| Gross Margin | 83.42% |
| Operating Margin | -33.3% |
| Pretax Margin | -27.71% |
| Profit Margin | -27.87% |
| EBITDA Margin | -33.3% |
| EBIT Margin | -33.3% |
| FCF Margin | -12.43% |
Dividends & Yields
APLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for APLS is $42, which is 109.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $42 |
| Price Target Difference | 109.1% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
Scores
| Altman Z-Score | -1.62 |
| Piotroski F-Score | 3 |